Adipotide peptide sits at an interesting intersection of vascular biology and metabolic research. If you are a qualified researcher or laboratory scientist exploring adipose-tissue vasculature, targeted peptide delivery, or prohibitin-related models, this compound has generated a real body of preclinical data worth understanding. PeptideValidation.com supplies research-grade Adipotide as a 10 mg lyophilized peptidomimetic designed for controlled laboratory studies. This article walks through what the compound is, how researchers design protocols around it, and what the preclinical literature actually shows.

What Is Adipotide Peptide?

Adipotide is a peptidomimetic compound that targets the vasculature supplying white adipose tissue. It binds prohibitin on endothelial cells lining fat-depot blood vessels, triggering apoptosis in those cells and reducing local blood supply. Preclinical models show this mechanism produces measurable reductions in adipose tissue mass without targeting systemic vasculature.

Adipotide belongs to a class of targeted compounds called peptidomimetics. These are molecules that mimic the structure and function of natural peptides while offering improved stability or binding specificity. The compound's full research name is CKGGRAKDC-GG-D(KLAKLAK)2, a mouthful that encodes two functional domains joined by a short glycine linker.

The first domain, CKGGRAKDC, is a homing sequence. It binds prohibitin, a protein expressed on the luminal surface of endothelial cells that line the blood vessels feeding white adipose depots. This binding is selective. Studies in primate models demonstrated that the compound preferentially accumulates in adipose vasculature rather than distributing evenly across systemic endothelium.

The second domain, D(KLAKLAK)2, is a pro-apoptotic sequence. Once the homing domain anchors the molecule to the target cell, this sequence disrupts mitochondrial membranes and initiates programmed cell death. The result is a reduction in the vascular supply to the fat depot, which is followed by a measurable decrease in adipose tissue volume.

Researchers studying metabolic biology, adipose-tissue remodeling, or vascular targeting will find Adipotide relevant as a mechanistic tool. It is supplied by PeptideValidation.com as a lyophilized powder at 10 mg per vial, batch-verified by HPLC and mass spectrometry, and intended strictly for in vitro and controlled in vivo preclinical research settings.

Prohibitin as the Molecular Target

Prohibitin is a membrane protein overexpressed on adipose endothelial cells. Adipotide exploits this selective expression to home in on fat-depot vasculature, making prohibitin the molecular anchor that gives the compound its tissue-targeting specificity in research models.

Understanding why Adipotide targets adipose tissue specifically requires a short detour into prohibitin biology. Prohibitin (PHB) was originally identified as a nuclear protein involved in cell-cycle regulation, but subsequent research revealed a second pool of prohibitin on the outer leaflet of certain endothelial cells.

The key observation, first published by Kolonin and colleagues around 2004, was that PHB surface expression is markedly elevated on endothelial cells within white adipose depots compared with other tissues. This differential expression creates a selectivity window that the CKGGRAKDC homing sequence exploits with reasonable precision in animal models.

For laboratory researchers, this has two practical implications. First, experiments designed to test vascular-targeting peptides can use Adipotide as a positive control or a mechanistic comparator for novel PHB-binding sequences. Second, studies examining adipose-tissue regression or remodeling can apply Adipotide to produce a reproducible reduction in fat-depot vascularity, then interrogate downstream effects on adipokine secretion, immune infiltration, or metabolic parameters.

When designing any assay around prohibitin targeting, researchers should confirm PHB surface expression in their specific cell line or tissue preparation before drawing conclusions. Expression levels vary between species and between subcutaneous and visceral depots, so characterizing your model system first saves significant time downstream.

Adipotide Peptide Dosage: What Preclinical Data Shows

Preclinical dosage for Adipotide in primate studies ranged from approximately 0.14 mg/kg to 1 mg/kg administered daily or on alternating days over treatment windows of 4 to 28 days. Rodent studies have used broader ranges. Researchers should calibrate dosage to their specific model, endpoint, and institutional approval.

Adipotide peptide dosage is one of the most searched questions in this research space, and for good reason. The compound has been tested across species, and the figures vary considerably depending on the model and the experimental endpoint.

In the most-cited primate study (Kolonin et al., published in Science Translational Medicine), obese rhesus macaques received subcutaneous injections at 0.14 mg/kg per day over 28 days. Animals showed reductions in body weight and waist circumference, along with decreased kidney volume on imaging. At higher doses, nephrotoxicity became a measurable concern, which is a consistent finding across the Adipotide literature.

Rodent studies have explored a wider range, from roughly 0.5 mg/kg to 10 mg/kg, depending on administration route and study duration. Because dose-response curves differ between species, direct numeric translation from rodent to primate data is not valid without independent dose-finding work.

For laboratories working with the 10 mg lyophilized format supplied by PeptideValidation.com, reconstitution in sterile water or acetic acid buffer is typical. Aliquoting into single-use volumes avoids repeated freeze-thaw cycles that can degrade the compound. Stability data suggest lyophilized Adipotide retains integrity for up to 24 months at -20 degrees C when kept dry and light-protected, though researchers should verify each batch COA for specific storage guidance.

No human dosage exists. This compound is for laboratory research only.

Interpreting Adipotide Peptide Results in Preclinical Studies

Preclinical Adipotide peptide results consistently show reductions in adipose tissue mass and body weight in animal models. Key measured outcomes include fat depot volume by MRI, circulating adipokine levels, and histological changes in vascular density within treated depots.

When researchers talk about Adipotide peptide results, they are generally referring to a specific cluster of outcomes reported in animal studies: reductions in fat-depot mass, changes in body composition metrics, and histological evidence of vascular rarefaction within adipose tissue.

The primate data are the most often cited because they represent the most translatable preclinical model. In the 2011 Science Translational Medicine study, 28-day treatment produced roughly 11% reduction in body weight and 27% reduction in waist circumference in treated animals versus controls. MRI imaging confirmed decreased retroperitoneal and subcutaneous fat volumes. Importantly, lean mass was largely preserved, which is a finding researchers frequently try to replicate in new model systems.

Rodent studies generally show larger percentage changes at higher doses, but the nephrotoxicity signal becomes more pronounced as dose increases. Research groups have investigated whether intermittent dosing schedules can maintain efficacy while reducing kidney burden. The data on this are mixed, and it remains an active area of study.

Laboratories designing experiments around Adipotide results should build in endpoint biomarkers beyond body weight. Circulating adiponectin and leptin levels, histological staining for CD31 to assess vascular density, and markers of apoptosis such as cleaved caspase-3 in adipose sections all provide mechanistic confirmation that the compound is acting through its intended pathway. Relying solely on weight change introduces confounds from fluid shifts and stress responses.

Adipotide Peptide Protocol Design for Laboratory Studies

A basic Adipotide research protocol includes four steps: (1) confirm prohibitin surface expression in the target cell or tissue model, (2) reconstitute lyophilized Adipotide in sterile vehicle to the working concentration, (3) administer at the validated dose and schedule with matched vehicle controls, and (4) collect pre-specified endpoints at defined time points including kidney function markers.

A well-structured adipotide peptide protocol reduces variability and makes results interpretable. Here is how experienced research teams approach this compound.

Before you start. Verify your model expresses surface prohibitin. Flow cytometry works well for cell-based assays. For tissue studies, immunofluorescence co-stained for PHB and an endothelial marker like CD31 gives you both expression confirmation and anatomical context.

Reconstitution. Lyophilized Adipotide typically dissolves readily in sterile water or in 0.1% acetic acid for better solubility at higher concentrations. Aim for a stock concentration that lets you deliver the target dose in a volume appropriate for your route of administration. Subcutaneous injection is the most commonly reported route in the published literature.

Controls. Include a vehicle control and, where feasible, a scrambled-sequence peptidomimetic control. The scrambled control confirms that observed effects depend on the specific homing and pro-apoptotic sequences rather than nonspecific peptide toxicity.

Monitoring. Kidney function should be tracked throughout any in vivo study. Serum creatinine and BUN at baseline and at regular intervals are standard. If creatinine rises more than 50% from baseline, most institutional protocols call for dose review.

Documentation. PeptideValidation.com provides batch-specific COAs including HPLC purity and MS confirmation. Attach the COA to your experimental records so the specific lot is traceable to your published results. Reproducibility in peptide research depends on this kind of documentation discipline.

Quality Verification: What to Check Before Running Experiments

Before incorporating Adipotide into any study, verify these four quality markers on the batch COA: HPLC purity of 95% or higher, mass spectrometry confirmation of the expected molecular weight (roughly 2978 Da for CKGGRAKDC-GG-D(KLAKLAK)2), a clear lot number, and documented storage conditions from the vendor.

Peptide quality verification is not optional. It is the step that separates reproducible data from confounded results that waste months of work.

HPLC purity is the primary metric. Most serious research applications call for 95% or higher purity by area percentage. A compound sitting at 88% purity carries a non-trivial load of truncated sequences and synthesis byproducts that can introduce biological noise, particularly in sensitive vascular-apoptosis assays where off-target effects are hard to distinguish from compound impurity.

Mass spectrometry confirms identity. For Adipotide, the expected monoisotopic molecular weight is approximately 2,978 Da. Any significant deviation signals either the wrong compound or a modification introduced during synthesis or storage.

Beyond the analytical data, look at the vendor's documentation practices. PeptideValidation.com evaluates certified vendors against objective criteria including transparent sourcing, batch-specific COA availability, independent lab testing, and documented quality management systems. This structure gives researchers a framework for comparing suppliers rather than relying on marketing claims.

Storage conditions matter more than many labs appreciate. Lyophilized peptides are generally stable at -20 degrees C for extended periods, but reconstituted solutions degrade faster. Keep working aliquots at 4 degrees C for no more than a week, and avoid repeated freeze-thaw cycles by preparing single-use aliquots at the time of reconstitution. These practical habits preserve the compound's biological activity between the manufacturing COA date and the day you run your assay.

Known Limitations and Safety Considerations in Research Settings

The primary safety signal in Adipotide preclinical studies is nephrotoxicity at higher doses, observed as elevated serum creatinine and structural kidney changes in primate and rodent models. Research protocols should include kidney function monitoring and dose titration to keep renal biomarkers within acceptable ranges for the study species.

No discussion of adipotide peptide side effects in a research context is complete without a frank look at the nephrotoxicity data. This is not a minor footnote. In the primate studies, doses above roughly 1 mg/kg per day produced measurable kidney tubule damage. The mechanism is not fully resolved, but hypotheses include off-target binding to renal endothelium or metabolic accumulation in tubular cells.

This finding has two implications for laboratory work. First, any in vivo study protocol must include kidney function biomarkers as safety endpoints, not just efficacy endpoints. Second, researchers exploring therapeutic applications in larger preclinical models should include dose-finding phases specifically designed to identify the maximum tolerated dose relative to efficacy.

For in vitro work, nephrotoxicity is obviously not a direct concern, but researchers should still run counter-screen assays on renal cell lines (HK-2 or primary proximal tubule cells work well) when characterizing a new peptidomimetic that uses the KLAKLAK pro-apoptotic domain. This is good practice for any mitochondria-disrupting sequence.

Beyond kidneys, the primate data showed transient reductions in water consumption during treatment, which resolved after the treatment period ended. Behavioral and biochemical monitoring consistent with your institutional protocols will capture similar signals in rodent studies.

Adiopotide is strictly a research compound. PeptideValidation.com supplies it for laboratory use only, and it is not approved or intended for human or veterinary use. Researchers must comply with all applicable institutional and regulatory guidelines when designing and conducting studies with this compound.

Frequently asked questions